What is the appropriate evaluation and treatment plan for a 37‑year‑old woman with elevated fasting insulin, severe vitamin D deficiency, low morning cortisol, low free thyroxine (free T4) with normal thyroid stimulating hormone (TSH), elevated total and free testosterone, low progesterone, pre‑diabetic fasting glucose and hemoglobin A1c, and findings consistent with polycystic ovary syndrome?

Comprehensive Evaluation and Management of PCOS with Metabolic Dysfunction

Immediate Diagnostic Priorities

This 37-year-old woman meets diagnostic criteria for PCOS with severe metabolic dysfunction requiring urgent endocrine evaluation for adrenal insufficiency, thyroid disease, and aggressive metabolic intervention. 1

Critical Abnormalities Requiring Immediate Action

The morning cortisol of 3.6 µg/dL is dangerously low and mandates urgent evaluation for adrenal insufficiency before any other intervention. Normal morning cortisol should exceed 10 µg/dL; values below 5 µg/dL indicate probable adrenal insufficiency requiring immediate endocrinology referral and possible corticosteroid replacement. 1 This finding takes absolute priority over PCOS management, as untreated adrenal insufficiency carries significant morbidity and mortality risk far exceeding PCOS complications. 1

The free T4 of 0.6 ng/dL is critically low (normal range typically 0.8–1.8 ng/dL) despite normal TSH of 1.51, suggesting central hypothyroidism or assay error. 1 This pattern—low free T4 with inappropriately normal TSH—indicates hypothalamic-pituitary dysfunction and requires urgent repeat testing with full thyroid panel including free T3, reverse T3, and consideration of pituitary imaging. 1 The combination of low cortisol and low free T4 with normal TSH raises concern for hypopituitarism.

PCOS Diagnosis Confirmation

The patient fulfills Rotterdam criteria for PCOS based on biochemical hyperandrogenism (elevated total testosterone 63 ng/dL and free testosterone 16 pg/mL) plus presumed ovulatory dysfunction (progesterone 0.3 ng/mL confirms anovulation). 1 A mid-luteal progesterone <6 nmol/L (approximately <0.2 ng/mL) definitively confirms anovulation and follicular arrest. 1

• Total testosterone of 63 ng/dL exceeds normal female range (typically <50 ng/dL), demonstrating 74% sensitivity and 86% specificity for PCOS when measured by LC-MS/MS. 1
• Free testosterone of 16 pg/mL is elevated (normal <9 pg/mL), showing superior 89% sensitivity and 83% specificity for PCOS diagnosis. 1
• DHEA of 145 µg/dL is within normal range for age 30–39 (normal <270 ng/mL), effectively excluding non-classical congenital adrenal hyperplasia. 1
• Estradiol of 89.3 pg/mL is tonically elevated, consistent with PCOS pathophysiology. 2

Severe Metabolic Dysfunction

The combination of fasting glucose 104 mg/dL, HbA1c 5.8%, and fasting insulin 25.1 µIU/mL confirms prediabetes with severe insulin resistance requiring immediate pharmacologic intervention. 3

• Fasting glucose 104 mg/dL meets American Diabetes Association criteria for impaired fasting glucose (100–125 mg/dL). 3
• HbA1c 5.8% falls in the prediabetes range (5.7–6.4%), indicating substantially increased risk of progression to type 2 diabetes. 3
• Fasting insulin 25.1 µIU/mL is markedly elevated (normal <10 µIU/mL), confirming severe insulin resistance. 1
• The glucose/insulin ratio of 4.1 (104/25.1) is at the threshold suggesting reduced insulin sensitivity (ratio >4 is normal). 1

The ALT of 31 U/L, while within laboratory reference range, is elevated for a premenopausal woman and suggests non-alcoholic fatty liver disease (NAFLD), which is highly prevalent in insulin-resistant PCOS patients. 3 ALT >19 U/L in women indicates hepatic steatosis; this patient requires hepatic ultrasound and repeat liver enzymes at 3 months. 3

Severe Vitamin D Deficiency

Vitamin D of 9.1 ng/mL represents severe deficiency (<20 ng/mL) requiring high-dose repletion, as 67–85% of PCOS women are vitamin D deficient, and this deficiency exacerbates insulin resistance, menstrual irregularities, and cardiovascular risk. 4, 5, 6 Vitamin D deficiency in PCOS is associated with calcium dysregulation, follicular arrest, worsened insulin resistance, and increased cardiovascular disease risk factors. 5, 6

---

Algorithmic Management Plan

Step 1: Urgent Endocrine Referral (Within 48–72 Hours)

Refer immediately to endocrinology for:

• ACTH stimulation test to confirm or exclude adrenal insufficiency (morning cortisol 3.6 µg/dL). 1
• Pituitary MRI if central hypothyroidism confirmed (low free T4 with normal TSH). 1
• Comprehensive pituitary hormone panel including IGF-1, morning cortisol, ACTH, prolactin (repeat with indwelling cannula to exclude stress elevation), LH, FSH. 1

Do not initiate PCOS-specific therapy until adrenal and thyroid function are clarified and treated, as these conditions carry higher morbidity/mortality risk. 1

Step 2: Complete PCOS Diagnostic Workup (Concurrent with Endocrine Evaluation)

Order the following tests to complete PCOS evaluation and exclude mimicking conditions:

• Repeat thyroid panel: Free T4, free T3, reverse T3, TSH to confirm central hypothyroidism versus assay error. 1
• Repeat prolactin: Morning resting sample via indwelling cannula (2–3 samples at 20–60 minute intervals) to exclude stress-related spurious elevation; values >20 µg/L are abnormal. 1
• 2-hour 75g oral glucose tolerance test: To definitively diagnose impaired glucose tolerance or diabetes (fasting glucose alone is insufficient). 1, 3
• Fasting lipid panel: Total cholesterol, LDL, HDL, triglycerides to assess dyslipidemia and cardiovascular risk. 1, 3
• Hepatic ultrasound: To evaluate for NAFLD given elevated ALT in setting of insulin resistance. 3
• Pelvic ultrasound (transvaginal if sexually active): To document polycystic ovarian morphology (≥20 follicles per ovary and/or ovarian volume ≥10 mL), though not required for diagnosis given confirmed hyperandrogenism and anovulation. 1

Do not order: Insulin or C-peptide levels (not recommended for routine PCOS evaluation; clinical signs of insulin resistance are sufficient). 1 Do not use AMH as a diagnostic test due to lack of assay standardization and validated cut-offs. 1

Step 3: Lifestyle Intervention (Initiate Immediately)

All women with PCOS require multicomponent lifestyle intervention regardless of BMI, as insulin resistance is universal in this condition. 3

Dietary prescription:

• Prescribe a daily energy deficit of 500–750 kcal (target intake 1,200–1,500 kcal/day if overweight). 3
• Reduce sugar-sweetened beverages, fruit juices, and refined carbohydrates. 3
• Increase legumes, whole grains, nuts, and seeds (rich in myo-inositol) to support cardiometabolic and reproductive health. 3
• Any culturally appropriate, nutritionally balanced diet is acceptable; avoid overly restrictive regimens. 3

Exercise prescription:

• Prescribe ≥150 minutes/week of moderate-intensity aerobic activity (or ≥75 minutes/week vigorous activity) in bouts of at least 10 minutes. 3
• Add resistance training involving major muscle groups on two non-consecutive days per week; both aerobic and resistance exercise improve insulin sensitivity independent of weight loss. 3
• Promote a goal of 10,000 steps per day, including 30 minutes of structured exercise, while minimizing prolonged sedentary periods. 3
• Implement SMART goal-setting with self-monitoring (activity trackers) and progress duration by ~5% each week. 3

Behavioral support:

• Screen for eating-disorder behaviors, anxiety, depression, and body-image concerns; refer to mental health services when indicated, as these factors markedly reduce adherence. 3
• Conduct biweekly visits during the first 3 months to review diet and exercise plans, then regular visits throughout the first 12 months. 3

Target a 5–10% body-weight reduction, which meaningfully improves metabolic parameters, ovulatory frequency, fertility potential, and androgen levels. 3 Even without measurable weight loss, adherence to healthy lifestyle improves quality of life and metabolic health. 3

Step 4: Pharmacologic Therapy (After Endocrine Evaluation)

For Metabolic Dysfunction (Initiate After Adrenal/Thyroid Status Clarified)

Initiate metformin 500 mg daily, titrating to 1,000–2,000 mg/day in divided doses for documented glucose intolerance and insulin resistance. 3 Metformin improves glucose tolerance, lowers diabetes and cardiovascular risk, reduces circulating androgen levels via enhanced insulin sensitivity, and provides modest weight loss. 7, 3

Consider adding a GLP-1 receptor agonist (liraglutide, semaglutide, or exenatide) if weight loss is insufficient after 3–6 months of lifestyle modification plus metformin. 7, 3 GLP-1 receptor agonists promote weight loss through suppression of postprandial glucagon, inhibition of glucose production, slowed gastric emptying, and increased satiety. 7 In PCOS trials, exenatide 10 µg twice daily and liraglutide 10–20 µg daily for 12 weeks improved hormonal parameters (FAI, total testosterone, SHBG), metabolic outcomes (fasting glucose, HOMA-IR), lipids, and anthropometric measures. 7

For Reproductive/Hormonal Dysfunction (If Not Seeking Pregnancy)

Prescribe combined oral contraceptives (COCs) as first-line hormonal therapy for PCOS patients not attempting conception. 3 COCs suppress ovarian androgen production, raise sex-hormone-binding globulin, regularize menstrual cycles, protect the endometrium from unopposed estrogen, reduce hirsutism and acne, and decrease endometrial cancer risk. 1, 3 A typical formulation is drospirenone 3 mg/ethinyl estradiol 20 µg in a 24/4 regimen. 3

Common pitfall: Do not use clomiphene citrate in this patient until fertility is desired and hypothalamic-pituitary-adrenal axis is normalized, as clomiphene is ineffective in functional hypothalamic amenorrhea and contraindicated with untreated adrenal insufficiency. 1

For Severe Vitamin D Deficiency

Prescribe high-dose vitamin D repletion: 50,000 IU weekly for 8–12 weeks, then maintenance 1,000–2,000 IU daily. 4, 5 Vitamin D supplementation may improve menstrual dysfunction, insulin resistance, and cardiovascular risk factors in PCOS, though current evidence is limited. 4, 5 Recheck 25-hydroxy-vitamin D level after 3 months; target level ≥30 ng/mL. 3

Step 5: Monitoring and Follow-Up

Schedule the following monitoring intervals:

• Biweekly visits during first 3 months to review diet/exercise adherence, then regular visits throughout first 12 months. 3
• At each visit: Measure weight, waist circumference, blood pressure. 3
• At 3 months: Repeat liver enzymes (ALT, AST) and hepatic ultrasound; if ALT remains >2× upper limit of normal or worsens, refer to hepatology. 3
• At 6–12 months: Repeat 2-hour oral glucose tolerance test, fasting lipid panel, cardiovascular risk assessment (weight, blood pressure). 3
• Every 6–12 months long-term: Lipid panel, blood pressure, weight to monitor lifelong increased risk of type 2 diabetes, dyslipidemia, and cardiovascular disease. 1, 3

---

Critical Pitfalls to Avoid

Do not delay endocrine referral for low cortisol and low free T4. These findings suggest life-threatening adrenal insufficiency and/or hypopituitarism that must be addressed before PCOS-specific therapy. 1

Do not use AMH levels for PCOS diagnosis due to lack of assay standardization, no validated cut-offs, and significant overlap between affected and unaffected women. 1

Do not withhold lifestyle intervention in normal-BMI PCOS patients; insulin resistance warrants treatment irrespective of weight. 3

Do not use insulin or C-peptide levels for routine PCOS evaluation; physical signs of insulin resistance (elevated BMI, acanthosis nigricans) are sufficient. 1

Do not use ultrasound for PCOS diagnosis in women <8 years post-menarche due to high incidence of multifollicular ovaries in this life stage. 1

Do not prescribe clomiphene citrate until fertility is desired and pituitary-adrenal function is normalized, as it is ineffective in functional hypothalamic amenorrhea and contraindicated with untreated endocrine disorders. 1

Do not ignore the elevated ALT; even "normal" ALT >19 U/L in women indicates hepatic steatosis requiring ultrasound and monitoring. 3

Do not use ginseng or herbal supplements as primary therapy; prioritize evidence-based lifestyle and pharmacologic interventions. 3